Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

CAP TODAY Webinars

Screening Smarter: CFTR2 and Variant Interpretation-June 11, 2025


Webinar presenter Karen Raraigh, MGC, CGCD, Assistant Professor of Genetic Medicine at Johns Hopkins University, discusses how expanded genetic testing is playing an increasingly vital role in the management of Cystic Fibrosis (CF), helping to elevate the standard of care.

Prognostic risk in cardiac patients using the Atellica IM High-Sensitivity Troponin I assay-March 19, 2025


Webinar presenters Melanie Pollan, PhD, Alan H. B. Wu, PhD, and Christopher DeFilippi, MD, discuss how the Atellica IM TnIH assay can be used to aid in offering rapid and accurate detection of AMI, helping lead to a faster diagnosis (versus contemporary Troponin assays); it can now also assist clinicians to identify future death and cardiovascular event risk based on the new prognosis indication for use.

The Journey to Fetal RHD Genotyping for Targeted RhIG Prophylaxis-March 11, 2025


Webinar presenters Gwen Clarke, MD, FRCPC, Hematopathology and Transfusion Medicine, Island Health, Victoria British Columbia Canada, and Clinical Professor, Department of Laboratory Medicine Pathology, University of Alberta, and Nancy Robitaille, MD, FRCPC, Vice-President, Transfusion Medicine, Héma-Québec, Montreal Canada Hematology-Oncology, CHU Sainte-Justine, Montreal, Canada and Clinical Professor, Department of Pediatrics, Université de Montréal discuss how advancements in non-invasive prenatal testing (NIPT) for fetal RHD are transforming targeted antenatal prophylaxis with RhIG.

Adopting Artificial Intelligence (AI) Image Analysis for Clinical Use: How do we get there?-January 29, 2025


Webinar presenters Marilyn M. Bui, MD, PhD, FCAP, Professor of Pathology and Scientific Director of Analytic Microscopy Core, Moffitt Cancer Center, and Savitri Krishnamurthy, MD, Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, and Patricia M. Raciti, MD, Scientific Director, Early Clinical Development and Translational Research, J&J Innovative Medicine, and Sylvia L. Asa, MD, PhD, Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center, Professor of Pathology, Case Western Reserve University discuss evaluation and implementation of AI tools for clinical use.

Aspyre® Clinical Test for Lung: A Rapid Alternative to Comprehensive Genomic Profiling


Webinar presenters Pranil K. Chandra, DO, Senior Vice President, Chief Genomics Officer PathGroup, and Nayan J. Sarma, PhD, HCLD/CC (ABB), Associate Director of Molecular Oncology PathGroup, and Jeff Gregg, MD, Vice President Medical Affairs, Biofidelity, Professor of Pathology and Laboratory Medicine, University of Nevada School of Medicine, address the gaps and limitations of CGP by using innovative simplified genomic profiling solutions that work for challenging samples not analyzable by CGP.